Schrödinger Signs a $2.7B Agreement with BMS to Develop and Commercialize Therapies in Multiple Disease Areas

November 24, 2020 Auto Bot Agreement, BMS, Commercialize, Develop, Discover, Disease, Multiple, Pharma, Schrödinger, Signs, Therapeutics 0

Shots:

  • Schrödinger to receive $55M upfront and is eligible to receive $2.7B as preclinical, development, regulatory & commercial milestones along with royalties on sales of each product commercialized by BMS
  • Schrödinger to grant BMS exclusive WW rights to develop & commercialize the development candidates emerges from the collaboration
  • The collaboration will merge Schrödinger’s computational platform & drug discovery capabilities with BMS’ expertise in development & commercialization to advance small molecule therapies targeting oncology, immunology & neurological disorders. The collaboration includes two of Schrödinger’s early-stage programs and additional undisclosed targets

Click here ­to­ read full press release/ article | Ref: BusinessWire | Image: Schrödinger

The post Schrödinger Signs a .7B Agreement with BMS to Develop and Commercialize Therapies in Multiple Disease Areas first appeared on PharmaShots.